Last reviewed · How we verify
placebo to match pioglitazone — Competitive Intelligence Brief
phase 3
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
placebo to match pioglitazone (placebo to match pioglitazone) — GlaxoSmithKline. This is an inert placebo formulated to match the appearance and administration of pioglitazone, a thiazolidinedione insulin sensitizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| placebo to match pioglitazone TARGET | placebo to match pioglitazone | GlaxoSmithKline | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- placebo to match pioglitazone CI watch — RSS
- placebo to match pioglitazone CI watch — Atom
- placebo to match pioglitazone CI watch — JSON
- placebo to match pioglitazone alone — RSS
Cite this brief
Drug Landscape (2026). placebo to match pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-match-pioglitazone. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab